DGX
Quest Diagnostics Incorporated
Stock
$233.33+2.24 (+0.97%)Close Oct 2, 2026
Cash flow statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.9B | $1.9B | $1.3B | $1.3B | $1.7B | $2.2B | $2.0B | $1.2B | $1.2B | $1.2B | $1.1B | $821M | $944M | $652M | $1.2B | $895M | $1.1B | $997M | $1.1B | $927M |
| Capital expenditures | $554M | $527M | $425M | $408M | $404M | $403M | $418M | $400M | $383M | $252M | $293M | $263M | $308M | $231M | $182M | $161M | $205M | $167M | $213M | $219M |
| Free cash flow | $1.3B | $1.4B | $909M | $864M | $1.3B | $1.8B | $1.6B | $843M | $817M | $923M | $823M | $558M | $636M | $421M | $1.0B | $734M | $913M | $830M | $850M | $708M |
| Stock-based compensation | $88M | $88M | $88M | $77M | $77M | $79M | $97M | $56M | $61M | $79M | $69M | $52M | $51M | $28M | $50M | $72M | $54M | $75M | $71M | $57M |
| Buybacks | — | $450M | $151M | $275M | $1.4B | $2.2B | $325M | $353M | $322M | $465M | $590M | $224M | $132M | $1.0B | $200M | $935M | $750M | $500M | $254M | $146M |
| Dividends paid | $363M | $353M | $331M | $314M | $305M | $309M | $297M | $286M | $266M | $247M | $223M | $212M | $187M | $185M | $108M | $65M | $71M | $75M | $78M | $77M |
| Dividends per share | $3.32 | — | — | — | — | — | — | — | — | $1.80 | $1.65 | $1.52 | $1.32 | $1.20 | $0.81 | $0.47 | $0.40 | $0.40 | $0.40 | $0.40 |
| Free cash flow margin | 11.7% | 12.3% | 9.2% | 9.3% | 13.3% | 17.0% | 16.8% | 10.9% | 10.8% | 12.5% | 11.4% | 7.4% | 8.6% | 5.9% | 13.6% | 9.9% | 12.6% | 11.1% | 11.7% | 10.6% |